Follow-up to: How long does afib last
Question explored with the scientific record
What factors predict whether afib becomes persistent after the first episodes?
The short version: left atrial size is the strongest structural predictor, but the evidence is thin on who gets stuck in persistent afib and why.
The J-RHYTHM II trial in hypertensive patients found that each 10 mm increase in left atrial diameter (LAD) raised the hazard of progression to persistent AF by 84% over one year, independent of other factors [1]. A CRT-device study in sicker hearts showed persistent AF at baseline carried an 8-fold odds of becoming permanent, and LAD over 52 mm combined with age over 71 gave an 18-fold odds [2]. In metabolic syndrome patients, epicardial fat thickness over 6.1 mm and galectin-3 over 15.9 ng/mL predicted recurrence after cardioversion with AUCs of 0.81 and 0.77 [7]. Circulating fibrocytes above 4% predicted 100% recurrence after ablation versus 16% below that cutoff [5].
| Predictor | Effect size | Population | Source |
|---|---|---|---|
| LAD per 10 mm | HR 1.84 for persistent AF | Hypertensive, paroxysmal AF | [1] |
| Persistent AF at baseline | OR 8.01 for permanent AF | CRT recipients | [2] |
| LAD >52 mm + age >71 | OR 18 for permanent AF | CRT recipients | [2] |
| Epicardial fat >6.1 mm | OR 4.21 for recurrence | Metabolic syndrome | [7] |
| Galectin-3 >15.9 ng/mL | OR 2.41 for recurrence | Metabolic syndrome | [7] |
| Fibrocytes >4% | 100% vs 16% recurrence | Persistent AF post-ablation | [5] |
The evidence comes from small, single-country or device-specific cohorts. No study compared treated to untreated patients. The biomarkers (galectin-3, fibrocytes) are not used in routine care. The strongest signal is structural: a left atrium that is already stretched or scarred tends to stay in AF.
My call: left atrial enlargement and fibrosis markers predict progression, but the evidence is moderate at best and comes from narrow populations.
Sources examined 10
-
Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: Results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II Study)
In hypertensive patients with paroxysmal atrial fibrillation, the study using data from the J-RHYTHM II Trial shows that greater left atrial dimension (LAD) predicts higher AF frequency (percent of AF days) and progression to persistent AF over 1 year, independent of several con…
DOI: 10.1016/j.hrthm.2011.07.035 -
Predictors of rhythm outcomes after cardiac resynchronization therapy in atrial fibrillation patients: When should we use an atrial lead?
In atrial fibrillation patients receiving cardiac resynchronization therapy with an atrial lead, about one-third progress to permanent AF and one-third maintain stable sinus rhythm over roughly 33 months, with persistent AF, larger left atrial diameter, and older age predicting …
DOI: 10.1002/clc.23527 -
Catheter Ablation of Atrial Fibrillation and Risk of Asymptomatic Cerebral Embolism
This is a comprehensive review of asymptomatic cerebral embolism after atrial fibrillation catheter ablation, summarizing incidence, mechanisms, risk factors, and strategies to mitigate risk while balancing ablation efficacy and patient outcomes.
DOI: 10.1111/pace.12336 -
Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease
In patients with persistent atrial fibrillation but no structural heart disease, plasma galectin-3 is elevated and independently predicts recurrence after catheter ablation, adding prognostic value beyond left atrial diameter.
DOI: 10.1093/europace/euv045 -
Elevated Circulating Fibrocytes Is a Marker of Left Atrial Fibrosis and Recurrence of Persistent Atrial Fibrillation
This study investigates the relationship between circulating fibrocytes and left atrial fibrosis, demonstrating that elevated levels of circulating fibrocytes are associated with increased fibrosis and recurrence of persistent atrial fibrillation after ablation.
DOI: 10.1161/JAHA.117.008083 -
Predicting recurrence of atrial fibrillation after electrical cardioversion: gauging atrial damage
An editorial summarizing clinical and serological predictors of recurrence of atrial fibrillation after electrical cardioversion, highlighting atrial damage biomarkers (TGF-beta1 and SDF-1a) and their potential as therapeutic targets based on Kim et al.'s study.
DOI: 10.1093/europace/eup436 -
Biomarkers of fibrosis and inflammation and the risk of arrhythmia recurrence after elective electrical cardioversion in patients with atrial fibrillation and metabolic syndrome
Metabolic syndrome increases six-month recurrence risk of atrial fibrillation after elective electrical cardioversion, with larger left atrial size, thicker epicardial fat, and higher circulating galectin-3 and IL-6 predicting recurrence.
DOI: 10.15829/1560-4071-2024-5857 -
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets
This 2024 review synthesizes current mechanistic insights into atrial fibrosis in atrial fibrillation, compares patterns and consequences for atrial conduction, evaluates imaging and biomarker diagnostic challenges, and surveys emerging antifibrotic therapies (pharmacologic, gen…
DOI: 10.3390/ijms26010209 -
Adipocyte-related genes analysis contributes to the prognosis of atrial fibrillation
A bioinformatic analysis of epicardial adipose tissue in atrial fibrillation identifies adipocyte-related senescent hub genes prognostic of AF progression, validated in human samples and linked to immune/inflammatory pathways.
DOI: 10.64898/2025.12.18.695292 -
Predicting arrhythmia recurrence post-ablation in atrial fibrillation using explainable machine learning
The study develops and validates an explainable multimodal machine learning framework that combines pre- and post-ablation left atrial imaging, simulations, and clinical data to predict atrial fibrillation recurrence after catheter ablation, and demonstrates interpretability of …
DOI: 10.1038/s43856-025-01058-4